First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium-Reference-Cited by-同舟云学术

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium

Published:2019-12 Issue:6 Volume:76 Page:861-867
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Dudani Shaan,Graham Jeffrey,Wells J. Connor,Bakouny Ziad,Pal Sumanta K.,Dizman Nazli,Donskov Frede,Porta Camillo,de Velasco Guillermo,Hansen Aaron,Iafolla Marco,Beuselinck Benoit,Vaishampayan Ulka N.,Wood Lori A.,Liow Elizabeth,Yan Flora,Yuasa Takeshi,Bjarnason Georg A.,Choueiri Toni K.,Heng Daniel Y.C.

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J Clin Oncol,2009

3. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions;Lalani;Eur Urol,2019

4. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial;Rini;Lancet,2019

5. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations;Kidney Cancer;2024-09-05

3. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study;Medicina;2024-07-02

4. Bio-markers of immuno-oncology;Journal of Pharmaceutical and Biological Sciences;2024-02-15

5. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study;Frontiers in Oncology;2024-02-12